235 related articles for article (PubMed ID: 15841634)
101. Eruptive epidermoid cysts resulting from treatment with imiquimod.
Marty CL; Randle HW; Walsh JS
Dermatol Surg; 2005 Jul; 31(7 Pt 1):780-2; discussion 782-3. PubMed ID: 16029707
[TBL] [Abstract][Full Text] [Related]
102. Noninvasive imaging, treatment, and microscopic confirmation of clearance of basal cell carcinoma.
Goldgeier M; Fox CA; Zavislan JM; Harris D; Gonzalez S
Dermatol Surg; 2003 Mar; 29(3):205-10. PubMed ID: 12614409
[TBL] [Abstract][Full Text] [Related]
103. Dermatoscopy-guided therapy of pigmented basal cell carcinoma with imiquimod.
Husein-ElAhmed H; Fernandez-Pugnaire MA
An Bras Dermatol; 2016; 91(6):764-769. PubMed ID: 28099598
[TBL] [Abstract][Full Text] [Related]
104. What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial.
Tinelli M; Ozolins M; Bath-Hextall F; Williams HC
BMC Dermatol; 2012 Oct; 12():19. PubMed ID: 23035730
[TBL] [Abstract][Full Text] [Related]
105. Long-term efficacy and safety of imiquimod 5% and fluorouracil 1% creams in medical monotherapy of complex eyelid basal cell carcinomas.
Singh M; Mehta Grewal A; Singh H; Sharma M; Kaur M; Gupta P; Zadeng Z
Eur J Ophthalmol; 2022 Jul; 32(4):2093-2100. PubMed ID: 34320864
[TBL] [Abstract][Full Text] [Related]
106. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells.
Barnetson RS; Satchell A; Zhuang L; Slade HB; Halliday GM
Clin Exp Dermatol; 2004 Nov; 29(6):639-43. PubMed ID: 15550144
[TBL] [Abstract][Full Text] [Related]
107. Treatment of non-melanoma skin cancer: immunotherapy as a viable option.
Shumack S; Rigel D
Acta Derm Venereol Suppl (Stockh); 2003 Sep; (214):18-22. PubMed ID: 14606278
[No Abstract] [Full Text] [Related]
108. Immunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up.
Gaitanis G; Bassukas ID
J Geriatr Oncol; 2019 May; 10(3):475-478. PubMed ID: 30219274
[TBL] [Abstract][Full Text] [Related]
109. Topical Imiquimod as a Treatment Option for Nodular Basal Cell Carcinoma: A Systematic Review.
Huang CM; Kirchhof MG
J Cutan Med Surg; 2020; 24(5):495-503. PubMed ID: 32527151
[TBL] [Abstract][Full Text] [Related]
110. Patient preferences for curettage followed by imiquimod 5% cream vs. surgical excision for the treatment of non-facial nodular basal cell carcinoma: a discrete choice experiment.
Sinx KAE; Mosterd K; de Coster D; Essers BA
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e41-e43. PubMed ID: 34416061
[No Abstract] [Full Text] [Related]
111. Pigmented basal cell carcinoma successfully treated with 5% Imiquimod cream.
Mehta V; Balachandran C
Indian J Dermatol; 2008; 53(3):140-1. PubMed ID: 19882014
[TBL] [Abstract][Full Text] [Related]
112. Randomized trial of topical ascorbic acid in DMSO versus imiquimod for the treatment of basal cell carcinoma.
Burke B; Bailie JE
Biomed Pharmacother; 2022 Apr; 148():112710. PubMed ID: 35217280
[TBL] [Abstract][Full Text] [Related]
113. Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma.
Martín-García RF
Dermatol Surg; 2005 Mar; 31(3):371-4. PubMed ID: 15841646
[TBL] [Abstract][Full Text] [Related]
114. Therapy of cutaneous squamous cell carcinoma in two retirement home residents.
Oster-Schmidt C; Dirschka T
J Dtsch Dermatol Ges; 2005 Sep; 3(9):705-8. PubMed ID: 16189865
[TBL] [Abstract][Full Text] [Related]
115. Combined imiquimod and acitretin for non-surgical treatment of basal cell carcinoma.
Ingves C; Jemec GB
Scand J Plast Reconstr Surg Hand Surg; 2003; 37(5):293-5. PubMed ID: 14649688
[TBL] [Abstract][Full Text] [Related]
116. Imiquimod: mode of action and therapeutic potential.
Chosidow O; Dummer R
Acta Derm Venereol Suppl (Stockh); 2003 Sep; (214):8-11. PubMed ID: 14606276
[No Abstract] [Full Text] [Related]
117. [Eruptive epidermoid cysts after imiquimod treatment of recurrent basal cell carcinoma : A case report].
Woltsche N; El-Shabrawi-Caelen L; Deinlein T; Kupsa R; Gschwandtner M; Hofmann-Wellenhof R; Zalaudek I
Hautarzt; 2019 May; 70(5):363-366. PubMed ID: 30694354
[TBL] [Abstract][Full Text] [Related]
118. Recurrence of a Basal Cell Carcinoma in a Vitiligo-like Area After Imiquimod Treatment.
Piqué-Duran E
Actas Dermosifiliogr; 2021 Jul; 112 Suppl 1():14. PubMed ID: 33901480
[No Abstract] [Full Text] [Related]
119. The combined effect of CO
El-Khalawany M; Saudi WM; Ahmed E; Mosbeh A; Sameh A; Rageh MA
J Cosmet Dermatol; 2022 May; 21(5):2049-2055. PubMed ID: 34333841
[TBL] [Abstract][Full Text] [Related]
120. Topical imiquimod 5% as an alternative therapy in periocular basal cell carcinoma in two patients with surgical contraindication.
Costales-Álvarez C; Álvarez-Coronado M; Rozas-Reyes P; González-Rodríguez CM; Fernández-Vega L
Arch Soc Esp Oftalmol; 2017 Feb; 92(2):93-96. PubMed ID: 27601079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
